TITLE:
Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy

CONDITION:
Peripheral Nervous System Diseases

INTERVENTION:
leteprinim potassium (Neotrofin)

SUMMARY:

      This study will assess the safety and efficacy of Neotrofin in treating the peripheral
      neuropathy that results from chemotherapy for cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 80 Years
Criteria:

        -  Patient must have diagnosis of cancer and be receiving or have received chemotherapy
             that has resulted in sensory or motor neuropathy.

          -  Sensory or motor neuropathy must be >/= grade 2 per Common Toxicity Criteria at
             baseline.

          -  In patients diagnosed with multiple myeloma, grade 1 sensory or motor neuropathy is
             acceptable.

          -  Patient must have normal hematological cell counts.

          -  Patient must have a life expectancy of >/= 3 months.
      
